This study is a multicenter, randomized, double-blind, placebo-parallel-controlled phase II clinical trial to evaluate the efficacy and safety of HRS-1780 compared with placebo in participants with primary aldosteronism. The study plans to enroll 60 participants.
Male or female, aged ≥ 18 years on the date of signing the informed consent form.
Diagnosed with primary aldosteronism.
No use of antihypertensive drugs before screening, or stable use of antihypertensive drugs.
Voluntarily sign the informed consent form before the trial, fully understand the trial content, procedures, and possible adverse reactions, and be capable and willing to comply with the protocol requirements to complete the study.
Has known secondary causes of hypertension.
Has previously undergone, or plans to undergo during the study period, adrenal-related surgeries, including adrenalectomy, adrenal ablation, etc.
Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m².
Has had any malignancy of an organ system within 5 years before screening.